SI1755642T1 - Aneksin V za preprečevanje rupture plaka - Google Patents

Aneksin V za preprečevanje rupture plaka

Info

Publication number
SI1755642T1
SI1755642T1 SI200530951T SI200530951T SI1755642T1 SI 1755642 T1 SI1755642 T1 SI 1755642T1 SI 200530951 T SI200530951 T SI 200530951T SI 200530951 T SI200530951 T SI 200530951T SI 1755642 T1 SI1755642 T1 SI 1755642T1
Authority
SI
Slovenia
Prior art keywords
annexin
binding
immunoglobulins
atherosclerosis
atherothrombosis
Prior art date
Application number
SI200530951T
Other languages
English (en)
Inventor
Anna Frostegard
Johan Frostegard
Original Assignee
Athera Biotechnologies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab filed Critical Athera Biotechnologies Ab
Publication of SI1755642T1 publication Critical patent/SI1755642T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Escalators And Moving Walkways (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Cosmetics (AREA)
SI200530951T 2004-04-15 2005-04-15 Aneksin V za preprečevanje rupture plaka SI1755642T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52138504P 2004-04-15 2004-04-15
EP05735990A EP1755642B1 (en) 2004-04-15 2005-04-15 Annexin v for preventing plaque rupture

Publications (1)

Publication Number Publication Date
SI1755642T1 true SI1755642T1 (sl) 2010-05-31

Family

ID=34966761

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200530951T SI1755642T1 (sl) 2004-04-15 2005-04-15 Aneksin V za preprečevanje rupture plaka

Country Status (15)

Country Link
US (1) US20080044404A1 (sl)
EP (1) EP1755642B1 (sl)
JP (2) JP2007532617A (sl)
CN (1) CN1997385B (sl)
AT (1) ATE454898T1 (sl)
AU (1) AU2005232436C1 (sl)
CA (1) CA2563408C (sl)
CY (1) CY1109959T1 (sl)
DE (1) DE602005018914D1 (sl)
DK (1) DK1755642T3 (sl)
ES (1) ES2356364T3 (sl)
PL (1) PL1755642T3 (sl)
PT (1) PT1755642E (sl)
SI (1) SI1755642T1 (sl)
WO (1) WO2005099744A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
WO2009077764A1 (en) * 2007-12-18 2009-06-25 Athera Biotechnologies Ab Compounds and methods for the treatment of vascular disease
ES2733902T3 (es) * 2008-02-22 2019-12-03 Annexin Pharmaceuticals Ab Compuestos y procedimientos para la prevención o tratamiento de reestenosis
CA2739445A1 (en) 2008-10-03 2010-04-08 Advanced Proteome Therapeutics, Inc. Site specific n-terminal modifications of proteins and conjugate formation
CA2740557C (en) 2008-10-17 2020-04-14 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
AU2009328507A1 (en) * 2008-12-19 2011-07-14 Medirista Biotechnologies Ab Oxidized cardiolipin as a novel pro-inflammatory factor
WO2011160845A2 (en) 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
WO2012136819A1 (en) 2011-04-05 2012-10-11 Athera Biotechnologies Ab Therapeutic and prophylactic methods, uses and compositions comprising anexin a5
WO2013109144A1 (en) * 2012-01-18 2013-07-25 Stichting Katholieke Universiteit Annexin a5 snp in atherosclerosis
GB2552853B (en) * 2015-09-17 2018-11-21 Annexin Pharmaceuticals Ab Purification of Annexin A5 from a composition that includes a calcium ion chelator
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB2552724B (en) * 2015-09-17 2020-05-06 Annexin Pharmaceuticals Ab Purification of Annexin A5 by anion exchange and affinity chromatography
CN105327042A (zh) * 2015-12-16 2016-02-17 刘爱玲 一种治疗颈动脉斑块的中药药膏及制备方法
GB201702144D0 (en) 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
CN108159421B (zh) * 2018-02-05 2021-05-18 苏州大学 磷脂酰丝氨酸阻断剂在制备治疗血小板数量减少相关疾病药物中的用途
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
CN117897399A (zh) 2021-06-14 2024-04-16 Inserm(法国国家健康医学研究院) 突变的膜联蛋白a5多肽及其在治疗目的中的用途
WO2023143463A1 (en) * 2022-01-30 2023-08-03 Nanjing Reju Therapeutics , Inc. Fusion protein and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US5767247A (en) * 1994-11-11 1998-06-16 Noboru Kaneko Anti-annexin-V monoclonal antibodies, and preparation and use thereof
US6284475B1 (en) * 1997-07-11 2001-09-04 Mount Sinai School Of Medicine Of The City Of New York Assays for diagnosis of thrombophilic disease
US5932712A (en) * 1997-07-31 1999-08-03 Incyte Pharmaceuticals, Inc. Annexin binding protein
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
IL149145A0 (en) * 1999-11-05 2002-11-10 Warner Lambert Co Prevention of plaque rupture by acat inhibitors
WO2001066124A2 (en) * 2000-03-10 2001-09-13 Medinnova Sf Composition for the treatment of heart failure
GB0005867D0 (en) * 2000-03-10 2000-05-03 Medinnova Sf Method
ME00554B (me) * 2000-05-05 2012-03-20 Serono Lab KORIŠĆENJE IL-18 INHIBITORA ZA LIJEČENJE l/ILI PREVENCIJU ATEROSKLEROZE
IL135993A0 (en) * 2000-05-05 2001-05-20 Omrix Biopharmaceuticals Pharmaceutical composition for the treatment of fibrosis
EP1379266B1 (en) * 2001-02-21 2007-04-18 SurroMed, Inc. Modified annexin proteins and prevention and treatment of thrombosis
US20050013778A1 (en) * 2001-04-03 2005-01-20 Theseus Imaging Corporation Methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
ATE439588T1 (de) * 2001-05-04 2009-08-15 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
US20040042959A1 (en) * 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents

Also Published As

Publication number Publication date
AU2005232436C1 (en) 2010-08-26
PT1755642E (pt) 2010-04-20
WO2005099744A1 (en) 2005-10-27
CA2563408C (en) 2015-08-25
EP1755642B1 (en) 2010-01-13
DE602005018914D1 (de) 2010-03-04
ES2356364T3 (es) 2011-04-07
PL1755642T3 (pl) 2010-06-30
US20080044404A1 (en) 2008-02-21
AU2005232436A1 (en) 2005-10-27
CN1997385B (zh) 2012-01-11
AU2005232436B2 (en) 2010-03-11
CA2563408A1 (en) 2005-10-27
CN1997385A (zh) 2007-07-11
CY1109959T1 (el) 2014-09-10
ATE454898T1 (de) 2010-01-15
JP2012136536A (ja) 2012-07-19
JP2007532617A (ja) 2007-11-15
DK1755642T3 (da) 2010-05-10
EP1755642A1 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
PL1755642T3 (pl) Aneksyna V do zapobiegania pękaniu blaszek miażdżycowych
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
IN2012DN02589A (sl)
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
WO2004013172A3 (en) Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2007121188A3 (en) Compositions and methods of using r(+) pramipexole
WO2006109312A3 (en) Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2005089803A3 (en) Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
TN2012000059A1 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
CR11692A (es) USO DE VARIANTES DE IGF-I PEGiladas PARA EL TRATAMIENTO DE TRASTORNOS NEUROMUSCULARES
WO2007146983A3 (en) Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
WO2007135505A8 (en) Veterinary pharmaceutical compositions for the treatment of pain and inflammation
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
IL183481A (en) Combinations containing vegf-trap with 5-fluorouracil are useful in the treatment of neoplastic diseases
SI1622939T1 (sl) Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega
MX2008014134A (es) Novedosos polimeros cationicos hidrofobicamente modificados y composiciones para el cuidado personal de los mismos.
WO2005123113A3 (en) Interferon compositions and methods of use thereof
HK1137765A1 (sl)
NZ723206A (en) A method of improving liver function
WO2006103118A3 (en) Therapeutic use of scin, a staphylococcal complement inhibitor in inflammatory diseases
MX2007010322A (es) Extractos de planta y metodos y usos de los mismos.
WO2006023882A3 (en) Anti-perspirant compositions with improved properties